JNJ

234.89

+0.77%↑

UNH

275.5

-1.96%↓

ISRG

476.32

-0.68%↓

ABT

108.95

+0.36%↑

RDY

13.92

+1.09%↑

JNJ

234.89

+0.77%↑

UNH

275.5

-1.96%↓

ISRG

476.32

-0.68%↓

ABT

108.95

+0.36%↑

RDY

13.92

+1.09%↑

JNJ

234.89

+0.77%↑

UNH

275.5

-1.96%↓

ISRG

476.32

-0.68%↓

ABT

108.95

+0.36%↑

RDY

13.92

+1.09%↑

JNJ

234.89

+0.77%↑

UNH

275.5

-1.96%↓

ISRG

476.32

-0.68%↓

ABT

108.95

+0.36%↑

RDY

13.92

+1.09%↑

JNJ

234.89

+0.77%↑

UNH

275.5

-1.96%↓

ISRG

476.32

-0.68%↓

ABT

108.95

+0.36%↑

RDY

13.92

+1.09%↑

Kodu・Aktsiate loetelu・Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics Inc

Avatud

SektorTervishoid

25.99 0.74

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

25.44

Max

26.19

Põhinäitajad
By Trading Economics
Sissetulek	23M 7.4M
Müük	18M 99M
Aktsiakasum	0.06
Kasumimarginaal	7.468
Töötajad	342
EBITDA	23M 11M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+25.15% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	25. veebr 2026

Turustatistika
By TradingEconomics
Turukapital	813M 3.2B
Eelmine avamishind	25.25
Eelmine sulgemishind	25.99

Uudiste sentiment

By Acuity

36%

64%

111 / 352 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

12.42 / 14.93 Toetus ja vastupanu

Arcutis Biotherapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

3. veebr 2026, 23:11 UTC

Suurimad hinnamuutused turgudel

Omandamised, ülevõtmised, äriostud

Silicon Laboratories Shares Up On Report of $7 Billion Texas Instruments Acquisition Deal

3. veebr 2026, 23:50 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

3. veebr 2026, 23:50 UTC

Market Talk

Nikkei May Decline After Hitting All-Time High -- Market Talk

3. veebr 2026, 23:42 UTC

Market Talk

Gold Edges Lower on Possible Technical Correction -- Market Talk

3. veebr 2026, 23:41 UTC

Omandamised, ülevõtmised, äriostud

KKR Makes AI Play With $10.9B Asia Data-Center Deal

3. veebr 2026, 23:38 UTC

Tulu

AMD Sales Climb on Help From Data-Center Business -- Update

3. veebr 2026, 23:29 UTC

Omandamised, ülevõtmised, äriostud

KKR-Consortium Deal in STT GDC Is One of the Largest Digital-Infrastructure Transactions in Southeast Asia

3. veebr 2026, 23:27 UTC

Omandamised, ülevõtmised, äriostud

Netflix, Warner Defend Proposed Deal in Senate Hearing -- WSJ

3. veebr 2026, 23:25 UTC

Omandamised, ülevõtmised, äriostud

KKR-Consortium Expects Deal to Close by Early 2H of 2026

3. veebr 2026, 23:23 UTC

Omandamised, ülevõtmised, äriostud

KKR Consortium With Singtel to Own 75% and 25% Stake in ST Telemedia Global Data Centres

3. veebr 2026, 23:22 UTC

Omandamised, ülevõtmised, äriostud

KKR-Led Consortium to Buy Singapore-Based Global Data-Center Provider Valued at S$13.8B

3. veebr 2026, 23:19 UTC

Market Talk

Australia Gold Miners Tipped to Rally Higher -- Market Talk

3. veebr 2026, 23:19 UTC

Market Talk

Global Equities Roundup: Market Talk

3. veebr 2026, 22:56 UTC

Suurimad hinnamuutused turgudel

Omandamised, ülevõtmised, äriostud

Silicon Laboratories Shares Up On Report of $7B Texas Instruments Acquisition Deal

3. veebr 2026, 22:40 UTC

Tulu

Amdocs Extends Collaboration With T-Mobile

3. veebr 2026, 22:39 UTC

Tulu

Amdocs 1Q Adj EPS $1.81

3. veebr 2026, 22:39 UTC

Tulu

Amdocs 1Q Rev $1.16B

3. veebr 2026, 22:39 UTC

Tulu

Amdocs 1Q EPS $1.45 >

3. veebr 2026, 22:38 UTC

Tulu

Amdocs: Shimie Hortig to Succeed Shuky Sheffer as President and CEO, Effective March 31

3. veebr 2026, 22:30 UTC

Omandamised, ülevõtmised, äriostud

Bob Iger's Second Time as CEO Wasn't Great for the Stock. He Still Leaves Behind A Strong Legacy. -- Barrons.com

3. veebr 2026, 22:22 UTC

Omandamised, ülevõtmised, äriostud

Texas Instruments Nearing $7B Deal for Silicon Laboratories, Sources Tell FT

3. veebr 2026, 22:14 UTC

Tulu

AMD Expects to Scale AI Business to Tens of Billions in Annual Sales in 2027, CEO Says

3. veebr 2026, 22:13 UTC

Tulu

AMD Expects Data-Center Unit Sales to Jump More Than 60% a Year Over Next Three to Five Years, CEO Says

3. veebr 2026, 22:12 UTC

Tulu

AMD in Talks With Several Companies About At-Scale, Multi-Year Chip Deployments, CEO Says

3. veebr 2026, 22:10 UTC

Tulu

AMD CEO: Eight of 10 Biggest AI Companies Use Instinct Chip to Power Production Workloads

3. veebr 2026, 22:10 UTC

Tulu

Blackstone Stock, Alternative Managers, BDCs Dive as Software Woes Infect Private Credit -- Barrons.com

3. veebr 2026, 22:10 UTC

Market Talk

Key Drivers Underpinning Shaw's Bullish View of Gold Intact -- Market Talk

3. veebr 2026, 22:10 UTC

Tulu

AMD CEO: Enterprises Are Modernizing Data Centers to Have Compute Needed for New AI Workflows

3. veebr 2026, 22:09 UTC

Tulu

AMD CEO: Hyperscalers Expanding Infrastructure to Meet Growing Cloud-Services Demand in AI

3. veebr 2026, 22:09 UTC

Tulu

AMD CEO: Demand Accelerated Across Data Center, Gaming and PC

Võrdlus sarnastega

Hinnamuutus

Arcutis Biotherapeutics Inc Prognoos

Hinnasiht

By TipRanks

25.15% tõus

12 kuu keskmine prognoos

Keskmine 32 USD 25.15%

Kõrge 37 USD

Madal 30 USD

Põhineb 7 Wall Streeti analüütiku instrumendi Arcutis Biotherapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

7 ratings

Osta

Hoia

Müü

Põhineb 7 analüütiku instrumendi Arcutis Biotherapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

12.42 / 14.93Toetus ja vastupanu

Recent bearish events outweigh bullish events.

There is one bullish event.

Sentiment

By Acuity

111 / 352 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.